Although autologous tandem hematopoietic SCT has improved the prognosis of patients with advanced highrisk neuroblastoma, the results remain unsatisfactory. In an attempt to induce the graft-versus-tumor effect, we performed autologous PBSCT followed by allogeneic cord blood transplantation in three consecutive advanced neuroblastoma cases with marked BM infiltration and high MYCN amplification. Severe acute complications did not occur in any patient and they have maintained diseasefree survival for 37-60 months. This strategy appears to be feasible and effective for the treatment of extremely high-risk neuroblastoma cases.
Introduction
The prognosis of advanced neuroblastoma, especially extremely high-risk cases such as stage 4 and MYCNamplified stage 3, is very dismal. The survival rate of patients with stage 4 neuroblastoma after conventional multimodal chemotherapies is still as low as about 30%. [1] [2] [3] [4] [5] [6] To improve the prognosis of extremely high-risk neuroblastoma, high-dose chemotherapies followed by double or triple tandem auto-SCT have been performed. Although the 5-year EFS rate after tandem auto-SCT for these high-risk cases has improved to 47-62%, [7] [8] [9] these results are still unsatisfactory, particularly in cases with MYCN amplification. 9 For the treatment of neuroblastoma, allo-SCT has been considered as an alternative method when sufficient numbers of autologous stem cells could not be harvested, because the superiority of allo-SCT to auto-SCT has not been clearly demonstrated. 10, 11 However, allo-SCT was recently reported to induce a graft-versus-tumor (GVT) effect against advanced neuroblastoma in some cases. [12] [13] [14] We performed a tandem transplantation consisting of autologous PBSCT (auto-PBSCT) followed by allogeneic cord blood transplantation (CBT) in three consecutive pediatric patients with stage 4 neuroblastoma exhibiting high MYCN amplification. They are alive without disease recurrence for 37-60 months after CBT. The importance of minimizing the tumor burden by first performing auto-PBSCT and possibly inducing a strong GVT effect mediated by donor natural killer (NK) and T lymphocytes from the second allogeneic CBT is discussed.
Patients and methods
The three patients with stage 4 neuroblastoma with highly amplified MYCN were all male and the age at diagnosis was 14 months in cases 1 and 3, and 15 months in case 2 ( Table 1 ). The primary lesion was located in an adrenal gland in all the three cases. All three cases had BM infiltration, and cases 1 and 3 had multiple bone metastases. Case 2 had severe dyspnea caused by bilateral pleural effusion and ascites containing malignant cells. Case 3 had thrombocytopenic purpura over his entire body that was caused by marked BM infiltration of tumor cells. Histopathological studies of biopsy specimens of the primary lesions revealed unfavorable histology in cases 1 and 3, and a favorable histology in case 2. Chromosomal analysis of these samples showed 1p loss of heterozygosity in all the three cases. The MYCN gene was markedly amplified in all the three cases (4200 copies in cases 1 and 2, and 30 copies in case 3).
Before surgery, the three patients received three to five cycles of the 98A3 regimen consisting of CY (1. , and cases 2 and 3 received 1 cycle of the 98A3 regimen. Before the start of the tandem transplantation, abnormal MIBG uptake disappeared in all the three cases, and the disease status was very good partial response in cases 2 and 3, but partial response in case 1 because of a high urinary homovanillic acid (HVA) level.
PBSCs were harvested after the second to fourth courses of induction therapy in all cases. Before the first PBSC harvest, it was confirmed that BM infiltration by tumor cells became negative on microscopic examination in all cases. A portion of the PBSC (0.2 Â 10 6 CD34 þ cells per kg per dose) was infused after the third to fifth courses of chemotherapy for rapid hematopoietic recovery. In case 2, an HLA-matched sibling was born while the patient was receiving chemotherapy and the sibling's cord blood cells were harvested and stored in liquid nitrogen.
The conditioning regimens of auto-PBSCT consisted of 12. Prophylaxis for GVHD consisted of taclorimus (0.02 mg/ kg/day d.i.v.) or CsA (3 mg/kg/day, i.v.) and short-term (5 mg/m 2 on days 1, 3 and 6). Recombinant human G-CSF was given from day 4 until the ANC reached 0.5 Â 10 9 /L. To prevent severe veno-occlusive disease, low-dose heparin (10 U/kg/h) and lipoprostaglandin E1 (30 ng/kg/h) were administered from the start of conditioning to day 28. 13-cis retinoic acid was not given to these patients after CBT because of the difficulty in obtaining this agent in Japan and possible deterioration of skin symptoms by GVHD.
Written informed consent for tandem (autologous cord blood) SCT was obtained from the parents of each patient. 
Results
After auto-PBSCT, the mean lengths of time required for reaching an ANC of 0.5 Â 10 9 /L, reticulocyte count of 1% and a platelet count of 50 Â 10 9 /L without transfusion were 11.6 (10-13), 24 (13-30) and 20.3 (13-30) days, respectively (Table 2) . No severe toxicities were observed in any patient. After CBT, the mean lengths of time required for reaching an ANC of 0.5 Â 10 9 /L, reticulocyte count of 1% and platelet count of 50 Â 10 9 /L without transfusions were 26.3 (22-35), 47.7 (30-77) and 79.7 (63-97) days, respectively. Complete chimerism was confirmed by microsatellite methods using peripheral blood on days 42, 57 and 28 in cases 1, 2 and 3, respectively. Severe stomatitis was observed in all cases between 12 and 26 days post transplantation, but resolved spontaneously thereafter. Case 2 experienced engraftment syndrome and required treatment with methylprednisolone i.v. for 3 weeks. Case 1 experienced HHV-6 reactivation, and case 2 experienced reactivation of HHV-6 and HSV. Case 3 developed CMV viremia and needed administration of gancyclovir. No other bacterial and fungal infections and severe complications occurred in the three cases.
In case 1, grade I acute GVHD (stage 1 skin rash) and limited chronic GVHD (skin only) developed, but regressed spontaneously without medication, and the administration of tacrolimus was stopped at 8 months after uCBT. In case 2, acute and chronic GVHD did not occur and the administration of CsA was discontinued at 5 months after CBT. In case 3, grade II acute GVHD (stage 3 skin rash and stage 1 diarrhea) and extensive chronic GVHD (skin) developed but resolved by prednisolone (PSL) p.o. (2 mg/ kg/day), and CsA and PSL were withdrawn and finally stopped on days 346 and 516, respectively.
Although the urinary HVA level remained high (50 mg per mg creatinine) at 5 months after uCBT in case 1, radiographic analysis including computed tomography and MIBG scintigraphy did not reveal any evidence of relapse. The urinary HVA level gradually decreased with fluctuation and reached the normal range at 3 years after uCBT. In cases 2 and 3, tumor markers including serum neuronspecific enolase and urinary HVA and vanillylmandelic acid had become normalized before SCT, and were persistently maintained within the normal range post CBT. The three patients are alive without any evidence of relapse at 37-60 months after CBT. 
Discussion
We performed auto-PBSCT/allo-CBT tandem transplantation in three consecutive stage 4 neuroblastoma cases with highly amplified MYCN. Although platelet recovery tended to be delayed in the engraftment after CBT, severe acute complications including veno-occlusive disease did not occur in spite of the short interval from the first to second SCT. In this setting, it is important to infuse a sufficient number of cord blood cells to avoid delayed engraftment. This auto/allo tandem SCT was feasible for these young children and all the three patients have maintained disease-free survival.
The first reason why allo-SCT was selected for the second transplantation was to avoid infusion of PBSC that might be contaminated with neuroblastoma cells, because all cases had marked BM infiltration. The second reason was to attempt to induce the GVT effect. Recently, there were some clinical reports of a GVT effect against neuroblastoma as follows: minimal residual disease in BM disappeared after the cessation of immunosuppressant 13 or after donor lymphocyte infusion, 14 and abnormal uptake on MIBG imaging disappeared 3 years after haploidentical PBSCT from the patient's father. 12 In our case 1, the urinary HVA level became normal at 3 years after uCBT. During reconstitution of the immune system after CBT, T-cell recovery is very slow, but functional NK cells recover within 1 month, 15, 16 suggesting that alloreactive NK cells might have an important role in the GVT effect particularly in the early phase after CBT. As neuroblastoma cells either do not express HLA class I or express it at very low levels, they should be good targets for allo-reactive NK cells as previously demonstrated in in vitro studies. 17, 18 In this regard, selecting KIR ligand-incompatible cord blood in the GVHD direction may enhance the NK cell-mediated GVT effect as previously described in uCBT for acute leukemia. 19 However, considering the long period of time required to achieve CR after allo-SCT, a T cell-mediated GVT effect against neuroblastoma should also exist.
A stronger GVT effect can be expected by avoiding stronger immunosuppressant therapy. In this regard, uCBT has the advantages of greater tolerance of HLA mismatch and lower incidence of severe GVHD, when compared with unrelated BMT or PBSCT. It is also known that the GVT effect is exerted more effectively in patients with a very limited number of tumor cells, as demonstrated in renal carcinoma. 20 Jubert et al. 21 also pointed out that disease progression was rapid in refractory neuroblastoma patients with high tumor burden after uCBT using reduced intensity conditioning (RIC). Thus, minimizing the tumor burden as much as possible before CBT seems to be important for acquiring the maximal GVT effect. Therefore, we emphasize the need for auto-PBSCT before CBT.
Late severe toxicities after autologous tandem transplantation for high-risk neuroblastoma include growth hormone deficiency, dental problems and hearing loss. 22 The combination of auto-SCT and allo-SCT may increase the number and severity of complications after transplantation. Although our cases showed no severe acute complications, they all had growth retardation and one case showed renal tubular dysfunction. If post-CBT GVT effects against neuroblastoma become more clearly evident, RIC in CBT might be the next strategy to minimize severe complications in extremely high-risk neuroblastoma cases. uCBT with RIC was feasible even in heavily pretreated refractory neuroblastoma children. 21 The effectiveness of auto-PBSCT followed by RIC allo-SCT (including three uCBT) in five advanced neuroblastoma cases was also reported. 23 In this setting, selecting KIR ligand-incompatible cord blood might be the key to acquiring the maximal GVT effect by NK cells.
